Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan;10(2):45.
doi: 10.21037/atm-21-6230.

Implementation of a pathological diagnosis and treatment pathway may improve the molecular detection of lung cancer

Chao Shi #  1   2 , Bing Wei #  1   2 , Xiaohui Liu  3 , Lin Meng  3 , Chengzhi Zhao  1   2 , Yuxi Chang  1   2 , Rui Sun  1   2 , Zhongxian Zhang  4 , Yang Yu  3 , Jie Ma  1   2
Affiliations

Implementation of a pathological diagnosis and treatment pathway may improve the molecular detection of lung cancer

Chao Shi et al. Ann Transl Med. 2022 Jan.

Abstract

Background: The 2018 Guideline from the College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP) established a benchmark turnaround time (TAT), according to which the results should be available to the treating oncologist within 10 working days. This article focused on the application process of a new protocol for pathological diagnosis and gene testing pathway and a sample collector. We want to solve the problem that there are not enough puncture samples for gene testing, and the benchmark turnaround time of gene detection was long in clinic.

Methods: In this study, we established and validated a new protocol for a pathological diagnosis and treatment pathway that was tested in the Henan Cancer Hospital, China. The "Biology collector (BIOCO)" tool was designed by our team, was made of polyvinyl chloride (PVC) material (patent application number is 201820902335.6). It consisted of two round magnets on the collector that can be adsorbed on the microtome blade holder, thus making it to move arbitrarily. It collected specimens that were discarded when the wax block was trimmed. We analyzed the TAT, testing accuracy and anti-pollution of new protocol based on BIOCO, compared with the conventional process based on the Routine Collection (ROUCO).

Results: The new pathway adopts a parallel approach to conventional pathology and molecular pathology, which significantly shortens the TAT to 4-6 days. The use of the BIOCO tool can effectively save pathological samples, avoid cross-contamination, and reduce the time delay caused by re-sampling. Most importantly, its accuracy and effectiveness are consistent with conventional collection methods.

Conclusions: The new diagnosis and treatment pathway based on the BIOCO collector can be used as a practical approach for the molecular diagnostic platform of the hospital pathology department.

Keywords: New diagnosis pathway; turnaround time (TAT); “BIOCO” collector.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://atm.amegroups.com/article/view/10.21037/atm-21-6230/coif). XL, LM, and YY are from Novogene Co., Ltd., Beijing, China. The other authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Schematic diagram of the front, side, and back of biology collector (BIOCO) and schematic diagram of BIOCO adsorbed on the knife holder.
Figure 2
Figure 2
Routine diagnosis path patterns of lung cancer specimens in Henan cancer hospital. (A) Routine clinical diagnosis and treatment pathway of different specimens; (B) routine clinical diagnosis and treatment pathway of specimens from the medical consortium.
Figure 3
Figure 3
New clinical precise diagnosis and treatment pathway for lung cancer specimens from Henan Cancer Hospital.
Figure 4
Figure 4
Comparison of extraction efficiency between the biology collector (BIOCO) and Routine Collection (ROUCO) methods in 39 specimens. (A) DNA concentration measured by Nanodrop2000; (B) DNA concentration measured by Qubit.
See this image and copyright information in PMC

References

    1. Cao L, Long L, Li M, et al. The utilization of next-generation sequencing to detect somatic mutations and predict clinical prognosis of Chinese non-small cell lung cancer patients. Onco Targets Ther 2018;11:2637-46. 10.2147/OTT.S155995 - DOI - PMC - PubMed
    1. Lung Cancer Group, Respiratory Society, Chinese Medical Association . Expert consensus on molecular targeted therapy for advanced NSCLC (2013). Chinese Journal of Tuberculosis and Respiratory Diseases 2014;37:177-82.
    1. NCCN. The NCCN Non-small Cell Lung Cancer clinical practice guidelines in oncology (version 1.2021). Available online: http://www.nccn.org
    1. Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med 2013;137:828-60. Erratum in: Arch Pathol Lab Med 2013;137:1174. 10.5858/arpa.2012-0720-OA - DOI - PMC - PubMed
    1. Lindeman NI, Cagle PT, Aisner DL, et al. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. J Thorac Oncol 2018;13:323-58. 10.1016/j.jtho.2017.12.001 - DOI - PubMed